102 results about "Injections subcutaneous" patented technology

The invention provides a sustained-release microneedle for treating ill-conditioned pregnancy and a preparation method and application thereof, and relates to the technical field of biological medicines.The sustained-release microneedle for treating ill-conditioned pregnancy comprises a base and a needle tip on the base, the needle tip part of the gel microneedle is made of heparin medicine, and the needle tip part of the gel microneedle is made of gelatin. The heparin medicine comprises heparin, heparin sodium, low-molecular heparin, low-molecular heparin sodium or low-molecular heparin calcium; the needle point part comprises a heparin photo-crosslinking monomer, and the base comprises a biocompatible polymer matrix. The sustained-release microneedle for treating pathological pregnancy provided by the embodiment of the invention has good mechanical strength, skin permeability and anticoagulant activity, can reduce skin bruises caused by subcutaneous injection of heparin, improves abortion caused by infection and inflammation and abortion caused by APS (anti-phospholipid antibody syndrome), can realize sustained release of drugs and increase of drug loading capacity, and has good application prospects. Sustainable drug delivery is achieved, and frequent injection is avoided.

The present invention relates to the treatment of subjects having CD20-positive cell proliferative disorders (e.g., B cell proliferative disorders, such as non-Hodgkin's lymphomas or chronic lymphocytic leukemia). More specifically, the invention pertains to the treatment of subjects having a B cell proliferative disorder by subcutaneous administration of mosunetuzumab as a monotherapy or in combination with lenalidomide.

The invention relates to the technical field of pharmaceutical preparations, and discloses a high-drug-loading risperidone sustained release microsphere for subcutaneous injection and a preparation method thereof, and the preparation method comprises the following steps: mixing risperidone, polylactic acid and dichloromethane to obtain an oil phase; dissolving a pore-forming agent in water to obtain a pore-forming agent solution; mixing polyvinyl alcohol, sodium chloride and water to obtain a water phase; mixing the oil phase with the pore-forming agent solution to obtain primary emulsion; mixing and stirring the primary emulsion and a water phase until dichloromethane is completely volatilized to obtain microspheres loaded with speridone; mixing cellulose acetate, polyethylene glycol and an organic solvent to obtain a coating solution; and coating the risperidone-loaded microspheres with a coating solution to obtain the high-drug-loading risperidone sustained-release microspheres capable of being used for subcutaneous injection. According to the invention, the efficient drug loading is realized, the injection comfort is improved, the slow permeation and release of the drug are realized, and the onset speed and the long-acting treatment demand are balanced.

The invention belongs to the technical field of medical experimental animal models, and particularly relates to a construction method of a rabbit ear acne model for studying acne pathogenesis and drug curative effect. A healthy New Zealand large-ear white rabbit is selected, a testosterone solution is subcutaneously injected to induce endocrine disorder, oleic acid is smeared at an opening of an external auditory canal on the inner side of an ear, dermatobacterium acnes suspension is subcutaneously injected, and whether acne-like lesions such as erythema, papule and comedo appear on the skin of the ear or not is observed. The method is easy and convenient to operate, low in cost, good in repeatability, capable of simulating the pathological process of human acne and suitable for acne pathogenesis research and drug screening.

One method for treating Crohn's disease in a patient involves administering a specific antibody against IL-23, for example, guselkumab, in an initial subcutaneous dose and subsequent subcutaneous doses so that the patient responds to the antibody and meets one or more of the clinical objectives.

The present invention provides methods of using non-naturally occurring melanocortin analogs to increase body weight and / or increase food consumption in a subject having a kidney disease and / or a liver disease (e.g., chronic kidney disease, renal failure, non-alcoholic fatty liver disease (NAFLD)). Also provided are methods of stimulating appetite in a subject via administration of a non-naturally occurring melanocortin analogue. The non-naturally occurring melanocortin analogs may be present in pharmaceutical compositions and delivered via parenteral administration (e.g., subcutaneous injection). The methods improve appetite, increase food consumption, increase body weight, muscle mass, and / or fat mass in the subject.

Provided in the present disclosure are materials, devices, systems, and methods for performing cryo-surgery in a mammalian subject. More particularly, presented are a slurry, devices, systems, and methods for subcutaneously injecting the slurry into a patient in need of bodyfat reduction intervention. The slurry, devices, systems, and methods permit highly efficacious subcutaneous ice phase-change lipolysis while not requiring that the patient be placed under general anesthesia, nor requiring significant new surgical training among practitioners.

Provided herein are methods of treating a subject having a CD20 - positive cell-proliferative disorder (e.g., a B-cell proliferative disorder, e.g., non-Hodgkin's lymphoma or chronic lymphocytic leukaemia).SOLUTION: The present invention provides the treatment of a subject having a B-cell proliferative disorder by subcutaneous administration of mosnetuzumab as monotherapy or in combination with lenalidomide.SELECTED DRAWING: Figure 10

The utility model relates to the technical field of medical instruments, and discloses a hypodermic injection positioning card which comprises a card body, an injection area and a positioning area are divided on the card body, a plurality of injection holes are formed in the injection area, the positioning area is arranged in the center of the injection area, and the positioning area is of a through hole structure. An injection date identifier and a serial number identifier are also arranged in the injection area; the injection area is divided on the card body, the injection hole is formed in the injection area, and the injection date mark and the serial number mark are arranged, so that when the injection card is used, a nurse can know the date and the position for injection by observing the time mark and the serial number mark in the injection area, and meanwhile, the injection time is greatly shortened. Nursing personnel can quickly deduce the specific part of the last injection of a patient by observing the injection date mark and the serial number mark in the injection area and combining the actual date, and compared with the prior art, the injection device has the advantages that injection work is convenient to carry out, and the time needed by injection is shortened.

The invention relates to a cell membrane bionic drug-loaded carbon dot nano-material as well as a preparation method and application thereof. The nano-composite is prepared by the following steps: preparing carbon dots, cross-linking to form a reduction responsive carbon dot nano-cluster, sequentially loading chemotherapeutic drugs and coating a cancer cell membrane to form a nano-vaccine. After the nano vaccine is injected into the body of a mouse through caudal vein, the enrichment of the nano vaccine in a tumor part can be enhanced by utilizing the active tumor targeting characteristic of a cancer cell membrane, and tumor cells can be induced to generate immunogenic death through carried chemotherapy drugs and photothermal therapy, so that chemotherapy / photothermal / immune combined therapy on tumors is realized; the obvious anti-tumor effect is realized. In addition, as a nano vaccine, after subcutaneous injection, the nano vaccine can also utilize the tumor antigen carried by a cancer cell membrane and the adjuvant characteristics of the carbon dots to activate the anti-tumor immunity of an organism so as to prevent tumors, and has potential clinical application value.

The invention discloses a construction method of an endothelial cell knockout Cdc42 gene aggravated bleomycin induced pulmonary fibrosis mouse model, which comprises the following steps of: mating a Cdc42 gene conditional knockout mouse with a mouse (Tie2-CreER) of which the endothelial cell specifically expresses tamoxifen induced Cre recombinase to obtain a double-transgenic mouse (Cdc42fl / fl-Tie2-CreER); the Cdc42 gene is specifically knocked out in vascular endothelial cells under the induction of tamoxifen, and then pulmonary fibrosis is induced by subcutaneous injection of bleomycin. The model shows aggravated pulmonary fibrosis phenotypes, including collagen deposition increase, alveolar structure damage and fibrosis-related protein expression up-regulation, and is high in construction success rate and good in repeatability. The invention also provides an application of the model in research of systemic sclerosis related interstitial lung disease pathogenesis and screening of anti-pulmonary fibrosis drugs, and an application of the Cdc42 gene as a drug target, and provides an accurate and reliable tool for pulmonary fibrosis research.

The present application belongs to the technical field of biomedicine, and relates to an in vivo self-assembling system targeting the central nervous system for treating diabetes. The present application provides an in vivo self-assembling system targeting the central nervous system. The in vivo self-assembling system targeting the central nervous system is a recombinant plasmid expressing a nucleic acid molecule, wherein the nucleic acid molecule encodes a fibroblast growth factor-based fusion protein, and the fibroblast growth factor-based fusion protein comprises a propeptide, a peptide targeting the central nervous system, a linker peptide, and a fibroblast growth factor variant having an amino acid sequence as set forth in SEQ ID NO.1, which are sequentially linked. The in vivo self-assembling system targeting the central nervous system can cross the blood-brain barrier and specifically reach the central nervous system via routes other than intracranial injection, such as subcutaneous injection and intravenous injection. The system exerts a long-lasting blood glucose-lowering effect, without causing adverse reactions, thereby retaining the anti-diabetic activity of fibroblast growth factors and avoiding the tumorigenic risks thereof.

Injection device for subcutaneous gas injection, assembly and associated method. The present invention relates to a gas injection device (16) comprising: - a body (18), extending around a central axis (A-A'), - an application head (22) defining a bearing surface (46) of the device (16) on a body surface (13), - a fluidic system (20) extending within the body (18) around the central axis (A-A'), the fluidic system (20) comprising a gas reservoir and having a needle attachment member (56) for receiving a microneedle (58) and a gas distribution system connecting the reservoir to the attachment member (56), - an actuating member (24) mounted on the body (18) movable in translation along the central axis (A-A') around the fluidic system (22), - a detachable microneedle (58) configured to be fixed on the fixing member (56) of the actuating member (24). Figure for the abbreviation: figure 2

To provide a PARP1 inhibitor and its use.SOLUTION: PARP1 inhibitors and pharmaceutical compositions comprising such inhibitors are described herein. The subject compounds and compositions are useful for the treatment of cancer. The compounds described herein are administered to a subject in need thereof according to standard pharmaceutical practice, either alone or in combination with pharmaceutically acceptable carriers, excipients or diluents, in a pharmaceutical composition. In one embodiment, the compounds of the invention can be administered to an animal. The compounds can be administered orally or parenterally, including the intravenous, intramuscular, intraperitoneal, subcutaneous, rectal and topical routes of administration.SELECTED DRAWING: None

Disclosed herein, in part, is a method for administering a liquid pharmaceutical formulation containing a loop diuretic to a patient via subcutaneous injection. Methods for treating conditions such as fluid overload, congestion, edema, and hypertension in a patient in need thereof are also provided.

The invention belongs to the technical field of biological appliances for medical research, and particularly relates to a urinary surgery CP / CPPS model and a modeling method thereof. The modeling method comprises the following steps: (1) preparing prostate homogenate: taking rats of 4 months old, stripping prostate tissues under a sterile condition after the rats are killed, and grinding or homogenizing to prepare an injection suspension; (2) preparing a vaccine intraperitoneal injection: dissolving the inactivated vaccine freeze-dried powder into aluminum hydroxide gel normal saline to prepare the vaccine intraperitoneal injection; (3) injection of molding liquid: after anesthetizing the mouse, subcutaneously injecting prostate homogenate suspension, and intraperitoneally injecting vaccine intraperitoneal injection; and repeating the injection step until the mouse CP / CPPS model is formed. The modeling material disclosed by the invention can be conveniently purchased, the modeling material has common phenotypes of emotional abnormalities such as pain sensitization, anxiety, depression and the like of chronic pain after being molded, the phenotypes after modeling can be maintained for at least 90 days and can exceed half a year at most, the success rate of single-batch modeling is high, and the case fatality rate is low.

The present invention relates to a highly concentrated, stable pharmaceutical formulation of a pharmaceutically active anti-HER2 antibody, such as e.g. Trastuzumab (HERCEPTIN™), Pertuzumab or T-DM1, or a mixture of such antibody molecules for subcutaneous injection. In particular, the present invention relates to formulations comprising, in addition to a suitable amount of the anti-HER2 antibody, an effective amount of at least one hyaluronidase enzyme as a combined formulation or for use in form of a co-formulation. The formulations comprise additionally at least one buffering agent, such as e.g. a histidine buffer, a stabilizer or a mixture of two or more stabilizers (e.g. a saccharide, such as e.g. α,α-trehalose dihydrate or sucrose, and optionally methionine as a second stabilizer), a nonionic surfactant and an effective amount of at least one hyaluronidase enzyme. Methods for preparing such formulations and their uses thereof are also provided.

This invention discloses a method for improving a mouse model of ANCA-associated vasculitis induced by anti-GBM antibodies, relating to the field of animal model construction. The method involves subcutaneously injecting mice with 20 μg rMPO on Day 0; administering 10 μg rMPO on Day 7; subcutaneously injecting 250 μg / kg GCSF daily from Day 11 to 15; and injecting 100 μl of goat anti-GBM serum via the tail vein on Day 16 to obtain the improved mouse model. This method improves the existing anti-GBM antibody-induced ANCA-associated vasculitis mouse model by injecting GCSF. This model enhances the disease severity in ANCA-associated vasculitis mice, specifically reflecting the disease in renal pathology and proteinuria, making the differences more obvious and effectively improving the success rate of model establishment.

The invention relates to the technical field of protein engineering, particularly discloses a human-like fibronectin and a skin filling composition thereof, and provides a recombinant human-like fibronectin, the amino acid sequence of which is as shown in SEQ ID No.1, and the recombinant human-like fibronectin can promote adhesion or migration of skin fibroblasts, so that the human-like fibronectin can be used as a skin filling composition. And the lasting stability of the molecular structure can be maintained in subcutaneous tissues. The skin filling composition containing the recombinant human-like fibronectin can provide supporting and filling functions through subcutaneous injection, so that the purpose of correcting wrinkles is achieved.

Provided are methods for clinical treatment of complement-associated conditions comprising administering to the patient an anti-C5 antibody, or antigen binding fragment thereof, wherein the anti-C5 antibody, or antigen binding fragment thereof, is administered (or is for administration) subcutaneously according to a particular clinical dosage regimen (i.e., at a particular dose amount and according to a specific dosing schedule). In one embodiment, the patient has previously been treated with eculizumab (SOLIRIS®) or ravulizumab (ULTOMIRIS®); particularly intravenously administered SOLIRIS® or ULTOMIRIS®.

Providing modified insulin and glucokinase nucleic acids for treating diabetes SOLUTION: Reducing hyperglycaemia and maintaining euglycaemia are the goals of all therapeutic approaches to the T1DM and T2DM. Current therapy for most diabetics is based on regular subcutaneous injections of both short-acting and long-acting insulin preparations. The present disclosure relates to modified nucleic acid sequences encoding insulin and glucokinase, expression cassettes and delivery vectors comprising the same, and methods for their delivery to treat diabetes.SELECTED DRAWING: None

The utility model belongs to the technical field of medical instruments, and discloses a needle head for a pre-filling needle, the pre-filling needle and an injector. The tail end of the needle head is provided with a needle point and a liquid outlet, two to four side holes communicated with the liquid outlet are formed in the side wall of the needle head in the length direction of the needle head according to a certain distance, the side hole farthest from the needle point is defined as a first side hole, and the side hole closest to the needle point is defined as a second side hole. The distance between the far-end edge of the first side hole and the needle tip is smaller than or equal to 6.0 mm, and the distance between the near-end edge of the second side hole and the needle tip is larger than or equal to 3.0 mm. According to the needle head for the pre-filling needle, in the injection process, the diffusion area of liquid medicine can be enlarged, the injection force can be reduced, and the injection difficulty can be reduced, so that the needle head can be used for subcutaneous injection of liquid medicine with higher viscosity, and the structural strength of the needle head can be guaranteed while the holes are formed by reasonably arranging the positions of the side holes.

A robotic device is provided that allows for precise and automated administration of diosmin into animal models to investigate its cardioprotective effects in a rat model. [Solution] The robotic device of this invention integrates a robotic arm 102, a syringe pump 104, a central processing unit 106 (CPU), and sensors, enabling precise control of injection parameters such as dosage, speed, and injection site. The device supports intravenous, intraperitoneal, and subcutaneous injections and provides real-time feedback on the injection mechanism's position. It also features a stabilization mechanism to minimize movement during injection and integrates physiological monitoring tools for adjusting drug administration based on the animal's real-time response. Remote control is possible, increasing convenience and reducing the possibility of human error.

The invention provides application of malavirol in preparation of a medicine for treating osteoporosis, a malavirol sustained-release system and application of the malavirol sustained-release system, and relates to the technical field of medicines. The research of the inventor finds that malaviif restores the damaged macrophage intercellular function caused by OVX, removes apoptotic cells and reduces the release of inflammatory factors by antagonizing a CCR5 receptor and inhibiting the activation of a downstream signal channel of the CCR5 receptor, so that the inflammatory microenvironment in a marrow cavity is relieved, the bone homeostasis is recovered, the overexpression of osteoclasts is inhibited, and the osteoclast effect is improved. The composition is used for treating osteoporosis. According to the malaviif sustained release system provided by the invention, a drug library can be formed through subcutaneous injection, continuous release of malaviif is realized, the clinical compliance problems that the half-life period of malaviif is short and frequent administration is needed are solved, and a preferable medication scheme is provided for chronic disease management.

The present invention provides an injectable depot composition comprising enavogliflozin and low-dose liraglutide. A combination regimen of enavogliflozin and low-dose liraglutide provides a synergistic effect in the treatment of obesity compared with the single administration of either drug. Furthermore, compared with the single administration of liraglutide, the administered dose of liraglutide can be reduced, and thereby the direct causes of gastrointestinal and cardiovascular side effects of liraglutide can be mitigated. Furthermore, the present invention has the additional advantage of providing an effect for alleviating metabolic diseases and cardiovascular diseases related to blood glucose, blood lipids, blood pressure, fatty liver, and the like through combined administration with enavogliflozin.Furthermore, the depot composition of enavogliflozin and liraglutide according to the present invention can significantly improve treatment convenience and treatment compliance for patients compared to existing liraglutide formulations, which are injected subcutaneously once daily, by unifying the route of administration and increasing the cycle of administration.

The utility model relates to a portable subcutaneous injection pump medicine storage injection device which comprises a medicine storage chamber and an injection assembly which are connected through a connecting hose. The injection assembly comprises a guide steel needle, an indwelling hose and a fixing seat, the fixing seat comprises an inner fixing seat and an outer fixing seat which are sleeved inside and outside, the guide cylinder seat and the soft needle seat are arranged in the outer fixing seat and arranged at the top of the inner fixing seat in a sleeved mode, liquid inlet holes which are communicated with each other are formed in the inner fixing seat and the outer fixing seat, and the liquid inlet holes are communicated with an inner cavity of the connecting hose. According to the injection assembly, the indwelling hose is fixed through the inner fixing seat and the outer fixing seat which are sleeved inside and outside, the structure that the inner fixing seat and the outer fixing seat are sleeved inside and outside makes full use of space, the structure is compact, miniaturization of the whole injection pump is facilitated, the fixing seats can fully occupy an inner cavity of the indwelling hose seat, liquid medicine residues are reduced, and waste is reduced. The use cost of a patient is reduced.

The present application relates to the biomedical field, specifically relates to a glucose-responsive empagliflozin microneedle delivery system and application thereof.The glucose-responsive empagliflozin microneedle delivery system of the present application is characterized in that the microneedle delivery system is a microneedle patch, comprising a substrate and a microneedle array arranged on the substrate; the microneedle in the microneedle array contains glucose-responsive empagliflozin nanoparticles CB@E or PCB@E.The present application has the following technical effects: the empagliflozin nanoparticles of the present application have precise glucose-responsive drug release performance.The microneedle drug delivery system of the present application has the effect of long-term control of blood glucose.In a T2DM rat model, MN@CB@E exhibits long-acting blood glucose control effect, can reduce blood glucose to normal level within 4h and maintain for 24h, and the hypoglycemic duration is significantly better than that of subcutaneous injection of free empagliflozin (only maintains for 6h), and there is no risk of hypoglycemia after administration to healthy rats.

An implantable sensor system using one or more sensor implants comprised of micro-electrical mechanical system (MEMS) sensors for the accurate and continuous measurement of physiological hemodynamic signals such as diastolic and systolic blood pressure. Sensor implants are configured to be subcutaneously injected to a placement site adjacent a blood vessel. In some embodiments, sensors comprise micromachined ultrasonic transducers.

The present disclosure provides novel PH20 mutant enzymes that exhibit significantly enhanced aggregation stability, are useful for the development of pharmaceutical subcutaneous injection formulations, facilitate diffusion of pharmaceuticals in subcutaneous tissue, reduce the volume limitations for subcutaneous administration and alleviate swelling or pain from large volume subcutaneous injections.

The present disclosure relates to improved liquid pharmaceutical formulations for an antibody that binds to interleukin-1-β (IL-1β) that may be stored for long periods of time and that may be administered by both intravenous infusion and subcutaneous injection.